- Serotonin-noradrenaline-dopamine reuptake inhibitor
Serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRI) are a class of
psychoactive antidepressant s. They act uponneurotransmitter s in thebrain , namely,serotonin ,norepinephrine anddopamine . These three biogenic monoamines are associated with depression and increasing the availability in the brain is one method used to treat the condition.SNDRIs are so-called triple reuptake inhibitors, which elevate extracellular plasma concentrations of all three
monoamine neurotransmitter s,serotonin ,norepinephrine anddopamine in thesynaptic cleft . These compounds show high potency but low selectivity between the different monoamine transporter proteins. No SNDRIs are yet on the market, although the first of these agentstesofensine is currently in clinical trials, [cite web |url=http://www.neurosearch.com/Default.aspx?ID=118 |title=Tesofensine |accessdate=2007-08-20 |format= |work=] cite journal |author=Lehr T, Staab A, Tillmann C, "et al" |title=Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease |journal=British journal of clinical pharmacology |volume=64 |issue=1 |pages=36–48 |year=2007 |pmid=17324246 |doi=10.1111/j.1365-2125.2007.02855.x] and other compounds such asbrasofensine cite journal |author=Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P |title=The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets |journal=Mov. Disord. |volume=17 |issue=5 |pages=877–86 |year=2002 |pmid=12360536 |doi=10.1002/mds.10238] andGlaxoSmithKline 'sNS2359 [ [http://www.neurosearch.com/Default.aspx?ID=117 NS2359 ] ] are under development.It should be noted that some SNRI drugs such as
Venlafaxine (Effexor ) andSibutramine (Meridia/Reductil) are known to weakly inhibit the reuptake ofdopamine at high doses, and so while these drugs are selective for the serotonin and noradrenaline transporters at normal doses, they can start to act as SNDRIs when taken at doses above the normal therapeutic range.References
External links
* [http://www.biopsychiatry.com/antidepressants/triple.html www.biopsychiatry.com/antidepressants/triple.html]
* [http://www.drugresearcher.com/news/ng.asp?id=61172-antidepressant-glaxosmithkline-merck www.drugresearcher.com/news/ng.asp?id=61172-antidepressant-glaxosmithkline-merck]
* [http://www.currentpsychiatry.com/article_pages.asp?AID=4795 www.currentpsychiatry.com/article_pages.asp?AID=4795]
Wikimedia Foundation. 2010.